Drugs / CRD007
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01723618 | Nov 2012 | abdominal aortic aneurysm | RSPR Pharma AB | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01540604 | — | Becker muscular dystrophy, Duchenne muscular dystrophy | RSPR Pharma AB | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT02517372 Comparator | Oct → Dec 2014 | — | RSPR Pharma AB | Completed | No outcome recorded |
| Phase 2 | NCT02615080 Comparator | Nov 2015 → Feb 2017 | asthma | RSPR Pharma AB | Completed | No outcome recorded |
| Phase 2 | NCT02609334 Comparator | Mar → Jul 2015 | asthma | RSPR Pharma AB | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CRD007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02615080 ↗ |
| Known as | Pemirolast sodium | “"Low dose" of CRD007 (pemirolast sodium) given as a single dose” NCT02609334 ↗1“pemirolast sodium (CRD007)” NCT02517372 ↗ |
| Route | Oral | “CRD007 administered orally b.i.d for 14 weeks” NCT02615080 ↗ |